SYGNIS Signs Non-Exclusive Distribution Agreement with SOPACHEM
News Mar 19, 2015
SYGNIS AG has announced a distribution agreement with SOPACHEM for the commercialization of the TruePrime™ product family developed by SYGNIS and designed for whole genome amplification (WGA) in Belgium.
Under the terms of the agreement, SOPACHEM will promote, market, sell and support TruePrime™ products for primer-free WGA in Belgium. TruePrime™ is based on SYGNIS’ revolutionary novel multiple displacement amplification (MDA) technology addressing key challenges in NGS applications, increasingly demanded in fields such as oncology, pathology and clinical diagnostics.
SOPACHEM is a specialized distributor with a strong focus on life sciences, diagnostics, biobanking and analytical applications with a broad portfolio of innovative products and technologies for NGS, polymerase chain reaction (PCR) analysis, DNA extraction and purification, transfection, bio-imaging and instrumentation. Besides its headquarters in Belgium, SOPACHEM runs additional offices in the Netherlands and in Luxembourg.
TruePrime™ WGA products are available in two formats, containing 25 or 100 reactions. Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product is made available and can also be directly ordered through SYGNIS’ own TruePrime™ online shop under www.sygnis.com/shop.
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE